Vectura Group plc, of Chippenham, U.K., said it completed a clinical trial for VR315, a generic inhaled combination therapy comprising fluticasone and salmeterol, in the U.S. for asthma and chronic obstructive pulmonary disease. VR315 is delivered using Vectura's dry powder inhaler and formulation technology.